Custom Pharmaceuticals acquires new tablet press

Published: 29-Oct-2010
Manufacturing Finance

Responds to customer demand and is in line with investment plans

In response to increased customer demand and in line with company plans to invest in manufacturing facilities in the UK, Custom Pharmaceuticals has acquired a new Courtoy R150 tablet press.

The R150 is capable of producing 250,000 tablets per hour. It also includes the latest in process checking software allowing individual out of specification tablets to be rejected.

The R150 spearheads a round of investment in equipment, including a new Ytron Comill additional drying capacity and in stainless steel in-process drums from Mueller.

‘All of the new equipment is being validated and installed during Q4 2010 in readiness for a planned double-digit growth in output and revenues during 2011,’ said Nigel Richardson, chief executive of Custom Pharmaceuticals.

  • Companies:
  • Custom Pharma Services
See more

You may also like

Distribution

CDMOs deliver increased performance for pharma clients with agility and innovation

Read more
Emma Verkaik, Membership & Marketing Director at the BCMPA — the Association for Contract Manufacturing, Packing, Fulfilment & Logistics — gleans insights from members in the pharma sector regarding emerging trends, growth opportunities and the impact of increasing digitalisation, sustainability issues and ESG on the wider industry

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. HOOKIPA Pharma begins non-binding discussions to acquire Poolbeg Pharma The two pharmaceutical companies may create a clinical-stage biopharmaceutical company focused on the development and commercialisation of next-generation immunotherapies
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    How CDMOs can set a new gold standard when it comes to going green Sustainability is more than a feel-good initiative or a choice; it’s a strategic imperative. Not missing a beat, pharma companies have been making a concerted effort towards positive change, reports Tim Lowery, President of JSR Life Sciences and CEO, KBI Biopharma
  4. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  5. The new F-Gas Regulation and its impact on pharmaceutical freeze-drying Freeze-drying or lyophilization represents a pivotal process in the life sciences industry. During the past five decades, the technology involved has evolved into a complex, integrated system that balances both technical and biological specifications with economic, safety, and environmental concerns

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Distribution

CDMOs deliver increased performance for pharma clients with agility and innovation

Emma Verkaik, Membership & Marketing Director at the BCMPA — the Association for Contract Manufacturing, Packing, Fulfilment & Logistics — gleans insights from members in the pharma sector regarding emerging trends, growth opportunities and the impact of increasing digitalisation, sustainability issues and ESG on the wider industry
Containment

Custom Pharma Services to expand manufacturing capacity in Brighton

Acquires a new building to broaden its high containment manufacturing and development operations
Manufacturing

Custom Healthcare Group expands product development services

Custom Development Solutions division is in the process of setting up jv with Brighton University
Finance

HOOKIPA Pharma begins non-binding discussions to acquire Poolbeg Pharma

The two pharmaceutical companies may create a clinical-stage biopharmaceutical company focused on the development and commercialisation of next-generation immunotherapies
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

How CDMOs can set a new gold standard when it comes to going green

Sustainability is more than a feel-good initiative or a choice; it’s a strategic imperative. Not missing a beat, pharma companies have been making a concerted effort towards positive change, reports Tim Lowery, President of JSR Life Sciences and CEO, KBI Biopharma
Finance

Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China

New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
Finance

Newcells Biotech raises additional funding from investors

Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance
Subscribe now